



3. Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. *Cancer Cell* 2018;**34**:186–195.
4. Du X, Hu H. The roles of 2-Hydroxyglutarate. *Front Cell Dev Biol* 2021;**9**:651317.
5. Ma S, Jiang B, Deng W, Gu Z-K, Wu F-Z, Li T, et al. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. *Oncotarget* 2015;**6**:8606–8620.
6. Saha SK, Parachoniak CA, Bardeesy N. IDH mutations in liver cell plasticity and biliary cancer. *Cell Cycle* 2014;**13**:3176–3182.
7. Böttcher M, Mouggiakakos D. Immunometabolic regulation of anti-tumor T-cell responses by the oncometabolite d-2-Hydroxyglutarate. *Immunometabolism* 2019;**1**. doi:10.20900/immunometab20190007.
8. Friedrich M, Bunse L, Wick W, Platten M. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. *Curr Opin Oncol* 2018;**30**:368–374.
9. Ma L, Wang L, Khatib SA, Chang C-W, Heinrich S, Dominguez DA, et al. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Hepatol* 2021. doi:10.1016/j.jhep.2021.06.028
10. Zhang Y, Du W, Chen Z, Xiang C. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. *Exp Cell Res* 2017;**359**:449–457.
11. Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, et al. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. *Oncogene* 2013;**32**:528–535.
12. Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. *J Clin Invest* 2019;**129**:137–149.

**Ethics Approval** This study was approved by the Johns Hopkins Hospital IRB: IRB approval number CR00023377.

<http://dx.doi.org/10.1136/jitc-2021-SITC2021.944>